Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2479 clinical trials
  • None views
  • None views
  • None views
  • None views
  • None views
A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma

This is a multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of ATG-019, a dual inhibitor of PAK4 and NAMPT, alone or co-administered with starting dose of 500 mg niacin ER in patients with advanced solid tumors or non-Hodgkin's lymphoma …

  • 0 views
  • 16 Feb, 2024
  • 5 locations
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

This study will test whether immune cells modified to recognize B-cell non-Hodgkin lymphoma (NHL) can be successfully manufactured at the University of Colorado Anschutz and whether these cells can be administered with an acceptable safety profile.

b-cell lymphoma
mantle cell lymphoma
large b-cell lymphoma
flow cytometry
non-hodgkin lymphoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

However, a large number of clinical studies have shown that about 20% of patients with B-ALL and 50% of patients with B-NHL cannot achieve complete remission (CR) after CD19-CAR-T treatment. Targeting tumor microenvironment is an important new method to overcome the drug resistance of CAR-T cells.

b-cell lymphoma
large b-cell lymphoma
flow cytometry
non-hodgkin lymphoma
rituximab
  • 0 views
  • 05 Aug, 2020
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

hepatitis
chronic lymphocytic leukemia
non-hodgkin lymphoma
lymphoid leukemia
hodgkin's disease
  • 0 views
  • 16 Feb, 2024
  • 6 locations
Acalabrutinib Lenalidomide and Rituximab for the Treatment of CD20 Positive Stage III-IV Grade 1-3a Follicular Lymphoma

This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work …

grade 2 follicular lymphoma
stage iv grade 1 follicular lymphoma
follicular lymphoma
measurable disease
lenalidomide
  • 0 views
  • 16 Feb, 2024
  • 1 location